Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-escalation of anti-CD20 therapy in clinically and radiologically stable multiple sclerosis
NL-OMON51850Withdrawn
- Sponsor
- Erasmus MC
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Erasmus MC. Primary endpoint: Proportion of patients with new and/or enhancing T2 lesions on brain MRI. Planned start May 2022; status: withdrawn.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON51850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51850.